HC Wainwright Has Positive Outlook for ACTU FY2026 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU – Free Report) – Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, November 16th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.57) per share for the year, up from their previous forecast of ($0.61). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.52 EPS.

ACTU has been the subject of a number of other reports. Rodman & Renshaw initiated coverage on shares of Actuate Therapeutics in a report on Thursday, July 30th. They issued a “buy” rating and a $6.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Monday, September 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.50.

Read Our Latest Stock Report on Actuate Therapeutics

Actuate Therapeutics Trading Down 6.1%

NASDAQ:ACTU opened at $0.25 on Wednesday. Actuate Therapeutics has a 12 month low of $0.23 and a 12 month high of $7.90. The business’s 50-day moving average is $0.62 and its 200 day moving average is $1.88.

Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04.

Insider Buying and Selling at Actuate Therapeutics

In other Actuate Therapeutics news, CEO Daniel M. Schmitt purchased 140,844 shares of Actuate Therapeutics stock in a transaction dated Wednesday, October 28th. The shares were purchased at an average cost of $0.35 per share, for a total transaction of $49,295.40. Following the completion of the acquisition, the chief executive officer owned 442,560 shares in the company, valued at $154,896. This represents a 46.68% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 57.98% of the company’s stock.

Hedge Funds Weigh In On Actuate Therapeutics

A number of large investors have recently bought and sold shares of the business. ABS Direct Equity Fund LLC lifted its position in shares of Actuate Therapeutics by 46.4% during the second quarter. ABS Direct Equity Fund LLC now owns 73,186 shares of the company’s stock worth $112,000 after purchasing an additional 23,186 shares during the last quarter. HighTower Advisors LLC purchased a new position in Actuate Therapeutics in the 2nd quarter worth about $56,000. Susquehanna International Group LLP purchased a new position in Actuate Therapeutics in the 2nd quarter worth about $43,000. BlackRock Inc. purchased a new position in Actuate Therapeutics in the 2nd quarter worth about $138,000. Finally, Palogic Value Management L.P. purchased a new position in Actuate Therapeutics in the 2nd quarter worth about $153,000.

More Actuate Therapeutics News

These are some of the ACTU news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its loss-per-share forecasts for 2026 through 2028, including its FY2027 estimate from a loss of $0.51 to $0.22 per share and its FY2028 estimate from a loss of $0.50 to $0.25. It also narrowed estimates for several quarters in 2026 and 2027. The analyst maintained a Buy rating. Actuate Therapeutics analyst estimates
  • Negative Sentiment: HC Wainwright cut its price target to $10 from $15 and reduced its projected EPS for FY2029 ($0.15 to $0.04) and FY2030 ($1.28 to $0.52). The lower target and longer-term profit forecasts temper the more favorable revisions for earlier years, despite the Buy rating. HC Wainwright price target update

About Actuate Therapeutics

(Get Free Report)

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cancer. Its research focuses on elraglusib, an investigational small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a target involved in processes that can affect tumor growth and the tumor microenvironment. The company is evaluating elraglusib in clinical trials, including in combination with chemotherapy for patients with pancreatic cancer and other solid tumors. Elraglusib is not an approved medicine, and Actuate does not currently have marketed products.

Read More

Earnings History and Estimates for Actuate Therapeutics (NASDAQ:ACTU)

Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.